⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL56766 | 0.73 | — | — | |
| SCHEMBL2190608 | 0.71 | — | — | |
| SCHEMBL270155 | 0.69 | — | — | |
| SCHEMBL9058110 | 0.69 | — | — | |
| SCHEMBL14843502 | 0.67 | — | — | |
| SCHEMBL3493461 | 0.67 | — | — | |
| SCHEMBL2372013 | 0.67 | — | — | |
| SCHEMBL21751470 | 0.67 | — | — | |
| SCHEMBL4257793 | 0.65 | — | — | |
| SCHEMBL11189004 | 0.65 | FDPS (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170049781-A1 | HSP90 INHIBITOR COMBINATIONS | NOVARTIS AG (CH) | 2017-02-23 | — | — | US | claimed |
| EP-2370076-B1 | Pharmaceutical combination comprising a Hsp 90 inhibitor and a mTOR inhibitor | NOVARTIS AG (CH) | 2017-01-04 | — | — | EP | claimed |
| CN-105727297-A | PHARMACEUTICAL COMBINATION COMPRISING A HSP90 INHIBITOR AND A MTOR INHIBITOR | 诺华股份有限公司 | 2016-07-06 | — | — | CN | claimed |
| US-20140309192-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC, | 2014-10-16 | — | — | US | claimed |
| EP-2776407-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2014-09-17 | — | — | EP | claimed |
| US-20140242088-A1 | Hsp90 inhibitor combinations | NOVARTIS AG (CH) | 2014-08-28 | — | — | US | claimed |
| WO-2013070657-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-05-16 | — | — | WO | claimed |
| US-20120232011-A1 | Use of Rapamycin and Rapamycin Derivatives for the Treatment of Bone Loss | KNEISSEL MICHAELA (CH) | 2012-09-13 | — | — | US | claimed |
| EP-2370076-A2 | PHARMACEUTICAL COMBINATION COMPRISING A HSP 90 INHIBITOR AND A MTOR INHIBITOR | Novartis AG (CH) | 2011-10-05 | — | — | EP | claimed |
| US-20110230444-A1 | PHARMACEUTICAL COMBINATION COMPRISING A HSP 90 INHIBITOR AND A MTOR INHIBITOR | NOVARTIS AG (CH) | 2011-09-22 | — | — | US | claimed |
| EP-1608368-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A COMBINATION OF RAPAMYCIN OR ITS DERIVATIVE AND PIMECROLIMUS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE (IBD) | NOVARTIS AG (CH) | 2008-10-01 | — | — | EP | claimed |
| EP-1880723-A1 | Combination of mTOR inhibitor and antifolate compound | Novartis AG (CH) | 2008-01-23 | — | — | EP | claimed |
| US-20060173033-A1 | Use of rapamycin and rapamycin derivatives for the treatment of bone loss | KNEISSEL MICHAELA | 2006-08-03 | — | — | US | claimed |
| US-20060154952-A1 | Pharmaceutical compositions comprising a combination of rapamycin or its derivative and pimecrolimus for the treatment of inflammation-and ummunologically-mediated diseases | MOORE HENRIETTA | 2006-07-13 | — | — | US | claimed |
| EP-1646634-A1 | USE OF RAPAMYCIN AND RAPAMYCIN DERIVATIVES FOR THE TREATMENT OF BONE LOSS | Novartis AG (CH) | 2006-04-19 | — | — | EP | claimed |
| EP-1608368-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A COMBINATION OF RAPAMYCIN OR ITS DERIVATIVE AND PIMECROLIMUS FOR THE TREATMENT OF INFLAMMATION- AND UMMUNOLOGICALLY-MEDIATED DISEASES | Novartis AG (CH) | 2005-12-28 | — | — | EP | claimed |
| WO-2005049021-A1 | MATERIALS AND METHODS FOR INHIBITING NEOINTIMAL HYPERPLASIA | OY HELSINKI TRANSPLANTATION R & D LTD (FI) | 2005-06-02 | — | — | WO | claimed |
| WO-2005005434-A1 | USE OF RAPAMYCIN AND RAPAMYCIN DERIVATIVES FOR THE TREATMENT OF BONE LOSS | NOVARTIS AG (CH) | 2005-01-20 | — | — | WO | claimed |
| WO-2004082681-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A COMBINATION OF RAPAMYCIN OR ITS DERIVATIVE AND PIMECROLIMUS FOR THE TREATMENT OF INFLAMMATION- AND UMMUNOLOGICALLY-MEDIATED DISEASES | NOVARTIS AG (CH) | 2004-09-30 | — | — | WO | claimed |
| EP-0119675-A1 | Hydrocarbyl-substituted mono and bis succinimide having polyamine chain linked hydroxyacyl radicals and mineral oil compositions containing same | TEXACO DEVELOPMENT CORPORATION (US) | 1984-09-26 | — | — | EP | claimed |